The European Medicines Agency’s CHMP recommended approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer based on the ROSELLA trial.
|Videos|April 1, 2021
Ovarian Cancer: Frontline Therapy
Author(s)Rebecca Previs, MD
Dr. Rebecca Previs from the Duke Cancer Center reviews frontline therapy options for patients with advanced ovarian cancer.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on CancerNetwork
1
CELMoDs After T-Cell–Engaging Therapy in Multiple Myeloma
2
Key Takeaways for Multidisciplinary Lung Cancer Care From WCLC 2026
3
Neoantigen Vaccine Shows Encouraging Activity in Head and Neck Cancer
4
What Were the Key Hematologic Oncology Takeaways from SOHO 2026?
5